Date: 2017-05-30
Type of information: Granting of a patent
Product name: allogeneic human primary T-Cells that are engineered to be T-Cell Receptor (TCR)-deficient and express a Chimeric Antigen Receptor (CAR)
Compound: allogeneic human primary T-Cells that are engineered to be T-Cell Receptor (TCR)-deficient and express a Chimeric Antigen Receptor (CAR)
Therapeutic area: Autoimmune diseases - Cancer - Oncology - Infectious diseases
Action mechanism: cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy
Company: Celyad previously known as Cardio3Bioscience (Belgium)
Disease:
Latest news:
Patents:
- • On May 30, 2017, Celyad announced the issuance of United States Patent No. 9,663,763 relating to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a chimeric antigen receptor (CAR). US Patent 9,663,763 was examined under the Cancer Immunotherapy Pilot Program, also known as the “Patents 4 Patients” initiative. This is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This new patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of these granted patents strengthens Celyad’s position and further confirms its leadership in engineered cell therapy, and in the allogeneic CAR-T space.
- • On March 16, 2017, Celyad announced that the U.S. Patent and Trademark Office (USPTO) has decided to reject a new reexamination request of Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a CAR. The patent remains valid and enforceable. “This is the fourth time that our US Patent for Production of Allogeneic TCR-Deficient CAR-T cells is challenged and each time, the USPTO has been favorable to Celyad. This patent is key for the players that are developing in the US allogeneic CAR-T cell approaches and it places Celyad in a very good position to optimize the significant potential of its allogeneic platform, either on
our own or through strategic collaborations”, said Christian Homsy, CEO of Celyad.
- • On October 23, 2015, Celyad announced the issuance of United States Patent No. 9,181,527 relating to allogeneic human primary T-Cells that are engineered to be T-Cell Receptor (TCR)-deficient and express a Chimeric Antigen Receptor (CAR). The US 9,181,527 Celyad Allogeneic Patent significantly strengthens Celyad’s patent portfolio in the CAR T-Cell field and its leadership in engineered cell therapy since the granted product claims are not limited to specific CARs or specific methods of generating allogeneic CAR T- Cells, such as genome editing or genetic engineering. The patented products are applicable for use in treating various human disease conditions such as cancer, chronic infectious diseases, and autoimmunity. Celyad currently has pre-clinical studies underway to develop allogeneic cancer therapies by using a TCR Inhibitory Molecule, or “TIM”, in combination with a next generation CAR construct that incorporates a natural killer receptor. This proprietary process results in an off-the-shelf “weaponized” TCR-deficient NK CAR T-Cell aimed at eliminating or greatly reducing graft- versus-host-disease (GVHD).
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE:
OTC status:
Other news:
Is general: Yes
